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Abstract
Background: Intimin is an important virulence factor involved in the pathogenesis of enteropathogenic Escherichia
coli (EPEC) and enterohemorrhagic Escherichia coli (EHEC). Both pathogens are still important causes of diarrhea in
children and adults in many developing and industrialized countries. Considering the fact that antibodies are
important tools in the detection of various pathogens, an anti-intimin IgG2b monoclonal antibody was previously
raised in immunized mice with the conserved sequence of the intimin molecule (int388-667). In immunoblotting
assays, this monoclonal antibody showed excellent specificity. Despite good performance, the monoclonal
antibody failed to detect some EPEC and EHEC isolates harboring variant amino acids within the 338-667 regions
of intimin molecules. Consequently, motivated by its use for diagnosis purposes, in this study we aimed to the
cloning and expression of the single-chain variable fragment from this monoclonal antibody (scFv).
Findings: Anti-intimin hybridoma mRNA was extracted and reversely transcripted to cDNA, and the light and
heavy chains of the variable fragment of the antibody were amplified using commercial primers. The amplified
chains were cloned into pGEM-T Easy vector. Specific primers were designed and used in an amplification and
chain linkage strategy, obtaining the scFv, which in turn was cloned into pAE vector. E. coli BL21(DE3)pLys strain
was transformed with pAE scFv-intimin plasmid and subjected to induction of protein expression. Anti-intimin scFv,
expressed as inclusion bodies (insoluble fraction), was denatured, purified and submitted to refolding. The protein
yield was 1 mg protein per 100 mL of bacterial culture. To test the functionality of the scFv, ELISA and
immunofluorescence assays were performed, showing that 275 ng of scFv reacted with 2 mg of purified intimin,
resulting in an absorbance of 0.75 at 492 nm. The immunofluorescence assay showed a strong reactivity with EPEC
E2348/69.
Conclusion: This study demonstrated that the recombinant anti-intimin antibody obtained is able to recognize the
conserved region of intimin (Int388-667) in purified form and the EPEC isolate.
Background
Intimin, a 94-kDa outer membrane protein, mediates
the adhesion of enteropathogenic Escherichia coli
(EPEC) and enterohemorrhagic Escherichia coli (EHEC)
to enterocytes. Both enteropathogens are important cau-
sative agents of diarrhea. Besides, EHEC can cause acute
gastroenteritis and hemorrhagic colitis [1], and produce
severe/fatal renal and neurological complications as a
result of the translocation of Shiga toxins (Stx1 and
Stx2) across the intestinal wall.
Intimin is encoded by the E. coli attaching and effa-
cing (eae) gene, which is required for intimate adhesion
to epithelial cells and cytoskeletal reorganization [2].
The variable 280-amino acid C-terminal sequence of
intimin (Int280) defines many different intimin subtypes
[3-5], and up to now, several types and subtypes of inti-
min have been described and designated by Greek let-
ters [4,6-17]. In contrast, the N-terminal region of the
intimin molecule is conserved and, therefore, has been
used as a target for diagnostic purposes [4,18-20].
Monoclonal antibodies have been used as tools for the
detection of different pathogen antigens due to their
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intimin IgG2b monoclonal antibody was raised in
immunized mice with purified conserved intimin (int388-
667). In immunoblotting assays, it showed excellent spe-
cificity and reacted with several serotypes of EPEC iso-
lates. Despite good performance, the monoclonal
antibody failed to detect some EPEC and EHEC isolates
expressing different intimin subtypes, especially the
gamma subtype [20]. In addition, monoclonal produc-
tion from hybridoma is expensive and requires cell cul-
ture facilities.
Recombinant antibody (rAb) technologies involving
the handling of key antibody domains constitute an
option and have been increasingly used as alternatives
to monoclonal antibodies (mAbs) in medical diagnostic
and therapeutic applications [22]. A variety of rAb for-
mats have been modified for specific applications,
including engineered modifications to antigen binding,
valency, and molecular weight (MW). One of the most
popular types of rAbs is single-chain variable fragment
(scFv), as it has been successfully modified into a num-
ber of different Ab formats and is easily expressed by
several expression systems.
Several different molecular display formats have also
been described, including phage-display [23], ribosome
display [24,25] and cell-sur f a c ed i s p l a y[ 2 6 ] ,b yw h i c h
antigen-reactive Abs can be selected and affinity
matured. Usually, E. coli is the bacterial production sys-
tem of choice for small nonglycosylated rAb fragments,
including scFv [27].
Regarding diarrheagenic E. coli, recombinant antibo-
dies were developed against different virulence factors,
which were developed for different purposes. Kühne et
al. [28] produced recombinant antibodies that recognize
EspA and intimin of EHEC O157:H7. These antibodies
were converted to scFv format and cloned into pET22b
vector. By immunoblotting, the anti-intimin scFv pro-
duced revealed the exclusive recognition of intimin
gamma. The anti-EspA scFv produced relatively weak
signals in immunoblotting against EspA in whole-cell
preparations from serotypes O157 and O111, and no
signals were produced with O127 or O86 [28].
For the treatment of bovine colibacillosis caused by
enterotoxigenic E. coli (ETEC), Bhaskaran et al. [29]
developed a recombinant anti-F5 scFv fragment that
inhibits the hemmaglutination of horse red blood cells
by F5 protein, which would be expected to inhibit the
binding of F5-expressing ETEC to intestinal cells.
According to these authors, it would provide an effec-
tive, less expensive and animal-friendly alternative as a
prophylactic agent against colibacillosis. Also for
ETEC, but concerning anti-LT monoclonal antibodies,
Chung et al. [30] selected scFvs that specifically
reacted with intermediate forms of the B subunit of
LT toxin, with the potential to be used to study penta-
mer assembly in vivo. Thus, the generation of scFvs
with differential binding specificities opens up key
areas for the development of new therapeutics that can
block toxin formation in situ and thus be used for the
treatment of diarrheal diseases caused by E. coli and
Vibrio cholerae [30].
Prompted by the potential applications of rAb, we stu-
died the cloning and expression and structural and func-
tional analysis of the recombinant form (scFv) of
monoclonal anti-intimin IgG2b antibody, previously
obtained from animal immunization employing con-
served intimin.
Methods
Microorganisms and plasmids
E. coli JM 109 [31] was used for cloning techniques and
as negative control for intimin expression. E. coli BL21
(DE3)pLys or E. coli C43(DE3) were used to express the
recombinant protein. EPEC E2348/69 was used as inti-
min expression control. pGEM-T Easy vector for cloning
was acquired from Promega (Madison, WI, USA). The
pAE expression vector was used for expression of
recombinant proteins fused with six histidine residues
for nickel affinity chromatography [32].
Cloning of single-chain variable fragment (scFv) of
monoclonal anti-intimin antibody
Protocols for DNA manipulation were used as described
in [31]. Briefly, mRNA was extracted (Ilustra Quickprep
mRNA Purification Kit - GE Healthcare, UK) and rever-
sely transcripted to cDNA (First Strand cDNA Synthesis
Kit - GE Healthcare, UK) from anti-intimin hybridoma
cells [20] cultivated in RPMI medium (Invitrogen, Bra-
zil) plus 10% fetal bovine serum in culture flasks (TPP,
Switzerland) at 37°C in 5% CO2. Commercially available
primers [Light primer mix, Heavy primer1, Heavy pri-
mer 2 (GE Healthcare, UK)] were employed to amplify
the variable domain of heavy (VH) and light (VL) chains
of the antibody following the manufacturer’si n s t r u c -
tions. The cDNA inserts corresponding to VL and VH
were cloned into the pGEM-T Easy vector and
sequenced using M13 forward primer (5’-GTAAAAC-
GACGCCCAG-3’) and reverse primer (5’-CAGGAAA-
CAGCTATGAC-3’). One set of primers was designed to
amplify the heavy chain variable domain, where the for-
ward primer was complementary to the 5’ terminal
region of the chain and the reverse primer was comple-
mentary to the 5’ terminal region of the linker (DNA
fragment that encodes the [Gly4Ser]3 flexible linker that
joins the heavy and light chain variable domains). Also,
another set of primers was designed to amplify the light
chain variable domain, where the forward primer was
complementary to the 3’ terminal sequence of the linker
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sequence of chain.
The light chain was amplified with the linker
sequence, and then, the heavy chain was amplified with
the light chain-linker sequence to generate the scFv,
using the primers VH-forward and VL-reverse with the
respective restriction sites (Table 1; Figure 1). Platinum
Pfx DNA polymerase (Invitrogen, USA) was used in all
PCR amplification reactions to obtain scFv. The result-
ing 3’ non-adenylated PCR product was purified using
the Ilustra GFX PCR DNA and Gel Band Purification
Kit (GE Healthcare, UK) as described by the manufac-
turer and subjected to fill-in reaction of the 3’ end with
dATP. Thirty microliters of DNA were used with the
addition of 1 mM dATP, 1 μLM g C l 2,1μLo fT a q
DNA polymerase (Invitrogen, USA), 4 μL of 10× buffer
for a 40-μL reaction mixture. The mixture was incu-
bated at 72°C for 20 min. After 3’ adenine anchoring,
the DNA was cloned into pGEM-T Easy and used to
transform E. coli JM109 competent cells. The selected
colonies were subjected to PCR to confirm the presence
of the scFv insert. Purified plasmids were digested using
BamHI and HindIII and the scFv fragment cloned into
pAE expression vector digested with the same enzymes,
for expression with an N-terminal 6×His-Tag. pAE/scFv
vector was used for transformation of E. coli BL21(DE3)
pLys competent cells.
Recombinant antibody (anti-intimin scFv) expression,
solubility and immunodetection
pAE-scFv was introduced into E. coli BL21(DE3)pLys.
The clone was cultivated (37°C, 300 rpm) in 400 ml of
2YT broth containing 100 μg/ml ampicillin and 20 μg/
ml chloramphenicol until OD600 =0 . 5 .A tt h i sp o i n t ,
IPTG was added to a final concentration of 1 mM, and
the culture was continued for an additional 5 h under
the same conditions. The culture was centrifuged (4,500
× g, 15 min, 4°C), the pellet was resuspended in 30 ml
of PBS, pH 7.4, and the bacterial cells were disrupted in
a French press under 2,000 psi (Thermo Scientific,
USA). The bacterial extract was centrifuged (12,000 × g,
30 min, 4°C), and the pellet was resuspended in 30 ml
solubilizing buffer (50 mM Tris-HCl, pH 8.0; 200 mM
NaCl; 5 mM imidazole; and 8 M urea) for 18 h at 4°C
with constant mixing (100 rpm). The bacterial extract
before and after induction, as well as soluble and insolu-
ble protein fractions, was analyzed by 12% SDS/PAGE
followed by Coomassie Blue staining (Bio-Rad, USA) or
transferred to nitrocellulose membrane for Western blot
assay (Bio-Rad, USA). The membrane containing the
bacterial protein extracts was blocked with blocking buf-
fer (5% skim milk diluted in PBS) at 37°C for 30 min
and incubated with 1:3000 anti-histidine mouse antibody
(GE Healthcare, UK) diluted in blocking buffer at 37°C
for 30 min. The membrane was washed with PBS plus
0.05% Tween 20 (PBST) 3 times for 5 min, followed by
1:2000 goat anti-mouse IgG conjugated to peroxidase
(Zymed-Invitrogen, USA) diluted in blocking buffer at
37°C for 30 min. The membrane was then washed and
revealed with diaminobenzidine (DAB) plus H2O2.
Purification and refolding of the recombinant scFv anti-
intimin antibody obtained
The solubilized recombinant scFv was centrifuged
(12,000 × g, 4°C, 30 min) and the supernatant was puri-
fied by immobilized metal affinity chromatography
(IMAC) using Ni-Sepharose resin (GE Healthcare, UK).
The column was washed with solubilization buffer to
Table 1 Primers designed for scFv cloning and annealing
temperatures
Primers Sequence Annealing T°
VH
Forward
5’ GGATCCGTGCAGCTGCAGGAGTCTGG 3’ 60°C
VH
Reverse
Linker
5’ ACCGCCTCCACCGGAGACGGTGACCGTG 3’ 76°C
VL
Forward
Linker
5’ GGTGGCGGATCGGACATTGTGCTGACC 3’ 78°C
VL
Reverse
5’ AAGCTTTTAGTTTGATTTCCAGCTTGGTGCC 3’ 70°C
Heavy chain forward primer contains the restriction site BamHI (bold). At the
light chain reverse primer was inserted the restriction site HindIII (italic) and a
stop codon (bold/italic).
VH VL 
VH-F 
VHL-R 
VLL-F 
VL-R 
LINKER-VL 
VL-R 
LINKER 
VH-F 
VL-R  scFv 
A) 
B) 
C) 
Figure 1 Scheme of the PCR for scFv assembly. A: Amplification
of VH and VL chains using primers (arrows) containing a region
complementary to the linker (dotted line). B: Amplification of VL
chain connecting to the linker, generating the LINKER-VL fragment.
C: Amplification and linkage of VH to the LINKER-VL and anti-intimin
scFv amplification.
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was eluted with elution buffer (50 mM Tris-HCl, pH
8.0; 200 mM NaCl; 500 mM imidazole; and 8M urea).
Purified recombinant scFv antibody was analyzed by
12% SDS/PAGE, as described above.
The purified scFv was dialyzed against solubilization
solution containing 5 M urea for 12 h at room tempera-
ture using dialysis membrane with 8,000 Da cut-off.
Step-wise dialysis was conducted by changing buffers
with decreasing urea concentrations (3 M, 2 M, 1 M, 0.5
M and no urea). Considering the 1 M urea step, oxidized
glutathione (375 μM) was added to the buffer to facilitate
stable disulfide bond formation. The solubilized scFv was
concentrated in polyethylene glycol 6000 (PEG 6000) and
quantified by the Warburg-Christian method [33].
Tertiary and quaternary structure predictions
The tertiary structures of the conserved intimin N-terminal
region (int388-667) were predicted, based on amino acid
sequence deduced from published DNA sequence
[GenBank:CAS11487] and anti-intimin scFv generated in
the present work [GenBank:GU722326] (Table 2) using
I-TASSER server http://zhang.bioinformatics.ku.edu/
I-TASSER. The quaternary structure of the complex was
calculated using ZDOCK 3.0 full search [34]; http://zlab.
bu.edu/zdock, following a local refinement protocol of the
best evaluated model implemented in Rosetta Dock [35];
http://graylab.jhu.edu/docking/rosetta.
Functionality assays
The functionality of the purified anti-intimin scFv was
assayed by ELISA and immunofluorescence.
Sandwich ELISA assay with polyclonal anti-intimin antibody
A polystyrene plate MaxiSorp (Nunc, Denmark) was
coated with 0.05 M carbonate/bicarbonate buffer, pH 9.6,
containing serial dilutions of recombinant anti-intimin
scFv antibody 1:200 (1 μg) to 1:1600 (125 ng) for 18 h at
4°C. The wells were blocked with 5% skim milk diluted in
PBS buffer and then, 20 μg/ml purified intimin (Int388-667)
was added and incubated for 2 h at 37°C. The polyclonal
rabbit anti-intimin IgG enriched fraction was added in
serial dilutions from 1:200 (7.5 μg) to 1:3200 (470 ng) and
incubated for 30 min at 37°C. The detection was done
with goat anti-rabbit IgG conjugated to peroxidase (Invi-
trogen, USA) diluted 1:5000 and revealed with ο-phenyle-
nediamine (OPD). The absorbance was measured at 492
nm and the reaction without purified intimin was taken
for background noise subtraction. Between each reaction
step, washing was done with PBS buffer containing 0.05%
Tween 20. The purified intimin used in the assays was
obtained as described by Menezes et al [20].
Immunofluorescence
EPEC E2348/69 was cultivated in Luria-Bertani broth
(LB) at 37°C for 18 h with constant shaking (250 rpm).
One milliliter of the growth culture was centrifuged at
12,000 × g for 10 min and washed three times in PBS
buffer. The pellet was permeabilized in 4% Triton X-100
under constant shaking (200 rpm) for 10 min and
washed twice in PBS buffer, followed by 1% r-formalde-
hyde incubation for 20 min followed by two washes
with PBS. Immunofluorescence reaction was performed
using 44 μg/ml recombinant anti-intimin scFv for 1 h at
room temperature, followedb ya n t i - h i s t i d i n em o u s e
antibody incubation at 1:2000 dilutions for 1 h at room
temperature. Goat anti-mouse IgG conjugated to fluor-
escein isothiocyanate (FITC) (Sigma, USA) at 1:100 dilu-
tion was added and the mixture incubated for 1 h at
room temperature. One drop of the bacterial suspension
was placed on a glass slide and examined with a fluores-
cence microscope (Axioskop-Zeiss, Germany) under
1000× magnification. As negative control, the assay was
performed with E. coli K12 JM109.
Table 2 VH, linker and VL nucleotide sequence and
predicted amino acid sequence of VH, linker, VL and
conserved intimin (Gly388 - Lys667)
Nucleotide Sequences
CHAINS SEQUENCES [GenBank:GU722326]
VH GTGCAGCTGCAGGAGTCTGGACCTGAGGTGGTGAAGCC
TGGGACTTCAGTGAAGATATCCTGTAAGGCTTCTGGATA
CACGGTCACTGACTACTACATGAACTGGGTGAAGCAGAGC
CATGGAAAGAGCCTTGAGTGGATTGGAGATATTAATCTTG
ACAATCGTGATTGTAGTTATAACCAGAAGTTCCAGGACAA
GGCCACATTGACTGTAGACAAGTCGTCCAGCACAGTCTA
CATGGAGATCCGCAGCCTGACTTCTGAGGACTCTGCAGT
CTATTACTGTGCAAGTCAACTGGGTCACTGGGGCCAAG
GGACCACGGTCACCGTCTCC
Linker GGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGC
GGATCG
VL GACATTGTGCTGACCCAGTCTCCAGCTTCCTTAGCTGTATC
TCTGGGGCAGAGGGCCACCATCTCATACAGGGCCAGCAA
AAGTGTCAGTACATCTGGCTATAGTTATATGCACTGGAACC
AACAGAAACCAGGACAGCCACCCAGACTCCTCGTCTATCTT
GTATCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTG
GCAGTGGGTCTGGGACAGACTTCACCCTCAACATCCATCCTG
TGGAGGAGGAGGATGCTGCAACCTATTACTGTCAGCACAT
TAGGGAGCTTACACGTTCGGAGGGGGCACCAAGCTGGAAA
TCAAAC
Amino Acid Sequences
CHAINS SEQUENCES
VH VQLQESGPEVVKPGTSVKISCKASGYTVTDYYMNWVKQSHGKS
LEWIGDINLDNRDCSYNQKFQDKATLTVDKSSSTVYMEIRSLT
SEDSAVYYCASQLGHWGQGTTVTVS
Linker GGGGSGGGGSGGGGS
VL DIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQK
PGQPPRLLVYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEED
AATYYCQHIRELTRSEGAPSWKSN
Int388-667
[GenBank:
CAS11487]
GIDYRHGTGNENDLLYSMQFRYQFDKPWSQQIEPQYVNELR
TLSGSRYDLVQRNNNIILEYKKQDILSLNIPHDINGTERSTQKIQ
LIVKSKYGLDRIVWDDSALRSQGGQIQHSGSQSAQDYQAILP
AYVQGGSNVYKVTARAYDRNGNSSNNVLLTITVLSNGQVVD
QVGVTDFTADKTSAKADGTEAITYTATVKKNGVAQANVPVS
FNIVSGTAVLSANSANTNGSGKATVTLKSDKPGQVVVSAKT
AEMTSALNANAVIFVDQTKASITEIKADK
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Cloning strategy of the recombinant anti-intimin scFv
The amplified fragments corresponding to VL and VH
were cloned into pGEM-T Easy vector and sequenced
using the M13 primers (forward and reverse). The pre-
dicted amino acid sequences of VL and VH (Table 2)
were analyzed in the NCBI database (blast.ncbi.nlm.nih.
gov) using the BLAST tool, and a homology of over 90%
was verified with the published data of the variable
region of antibodies of the mice species Mus musculus.
Conserved regions of heavy and light chain variable
domains were used to design new primers containing
appropriate restriction sites for subsequent cloning into
expression vectors (Table 1).
Amplification products of approximately 300 bp were
obtained using these specific primers, corresponding to the
variable domains of light and heavy chains (VL and VH).
In order to obtain and connect the light and heavy chains
variable domains by the linker sequence, four PCR reac-
tions were performed, resulting in a product of approxi-
mately 700 bp (Figure 1), corresponding to the anti-intimin
scFv (scFv-int), which was subsequently cloned into pAE
expression vector. Transformed clones were screened by
colony PCR and sequenced (data not shown).
Expression of the recombinant anti-intimin scFv
To confirm the presence of the recombinant scFv fused
to 6 histidine residues in the extract of E. coli BL21
(DE3)pLys, samples were analyzed by 12% SDS/PAGE
(Figure 2) and immunodetected using mouse anti-His
antibody (Figure 3). The results showed the expression
of a 26.5 kDa protein, the predicted size of anti-intimin
scFv as inclusion bodies in the post-induction fraction
(Figure 2, lanes 3 and 5 and Figure 3, lanes 2 and 4).
Purification of the recombinant anti-intimin scFv
The insoluble protein produced was solubilized using 8 M
urea buffer and purified by immobilized metal affinity
chromatography (IMAC) using Ni-Sepharose resin. The
purified protein was then refolded, quantified and sub-
jected to analysis by SDS/PAGE (12%), revealing a protein
of 26.5 kDa, predicted for scFv (Figure 3, lane 4 and Fig-
ure 4,l a n e2 ). The final process yield was approximately
10 mg of refolded scFv per liter of bacterial culture.
Structural and functional analysis of the recombinant
anti-intimin scFv
The overall in silico analysis of the constructed models
revealed expected features corresponding to scFv (Figure
5 A )a n di n t i m i nd o m a i na r r a n g e m e n tt h a ti st y p i c a l l y
found in homologous molecules (Figure 5B). Both mod-
els were subjected to calculations concerning complex
formation. The final complex structure suggested that
  1        2         3         4         5 
97 - 
66 - 
45 - 
30 - 
20,1 - 
14,4 - 
kDa - 
Figure 2 Expression analysis of recombinant scFv-intimin. E. coli
BL21(DE3)pLysS total extracts analyzed by electrophoretic profile in
12% SDS/PAGE. Lane 1. Molecular weight marker (LMW 97 to 14.4
kDa). Lane 2. Total bacterial extract before induction. Lane 3. Total
bacterial extract 5 h after induction. Lane 4. Soluble fraction of
bacterial extract. Lane 5. Insoluble fraction of bacterial extract
(inclusion bodies) treated with 8 M urea. Recombinant protein of
interest indicated by the arrow.
 
 1               2              3                 4        
97 - 
66 - 
45 - 
30 - 
20,1 - 
14,4 - 
kDa - 
Figure 3 Immunodetection of recombinant scFv-intimin. E. coli
BL21(DE3)pLysS extracts were submitted to 12% SDS/PAGE,
transferred to nitrocellulose membrane and detected by
immunoblotting with mouse anti-His antibody. Lane 1. Total extract
as control of pre-induction. Lane 2. Total extract of bacterial cells
after induction. Lane 3. Soluble fraction of bacterial extract. Lane 4.
Insoluble fraction of bacterial extract (inclusion bodies) treated with
8 M urea. Recombinant protein containing 6-histidine residues
detected by anti-His antibody is indicated by the arrow.
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extent) would be mainly involved in the recognition of a
region corresponding to the connection between two
intimin388-667 Ig-like domains (Figure 5C).
The reactivity of the recombinant anti-intimin scFv
was investigated by sandwich ELISA assay in a checker-
board titration. The reactivity with 2 μg of purified inti-
min was observed until 125 ng of scFv (data not
shown). The best fit titration curve corresponded to 275
ng of scFv, in which the optimal absorbance was 0.75
using 7.5 μg of polyclonal rabbit anti-intimin IgG
enriched fraction (Figure 6). The functionality of recom-
binant scFv was tested by an immunofluorescence assay
that showed a strong reactivity of the permeabilized
EPEC E2348/69 cells with the scFv antibody (Figure 7).
As expected, the negative control, E. coli K12, was not
stained using the scFv antibody. These results demon-
strate that recombinant scFv produced in this work is
functional and recognizes either the conserved region of
intimin, used in the ELISA assay, or native intimin on
the permeabilized EPEC E2348/69 cells.
Discussion
Serotyping has been widely applied in the diagnosis of
gastrointestinal diseases caused by EPEC and EHEC, but
cannot be used for identifying these groups conclusively
[36]. Therefore, identification of the characteristic viru-
lence genes is an obvious choice for detection. PCR to
detect one or multiple virulence genes in the same reac-
tion has been a successful method for the detection of
EPEC and EHEC, as well as other DEC pathotypes.
Nevertheless, gene detection does not assure expression
of the corresponding virulence factor [20,37,38]. Among
the methods for detection of virulence factor expression,
immunoassays can be considered the first alternative,
for which polyclonal and/or monoclonal antibodies are
raised [19,39-41].
The great genetic diversity of intimin, demonstrated
by the description of at least 27 subtypes, makes difficult
its molecular detection, which is dependent on the pri-
mers sequences [11,17]. Moreover, a negative PCR result
may not indicate that intimin is absent. For this reason
the conserved region of this protein (Int388-667) was used
1                                            2 
45 - 
30 - 
kDa 
Figure 4 SDS/PAGE analysis of purified recombinant scFv-
intimin after purification by affinity chromatography to nickel-
containing Sepharose. Lane 1. Molecular weight marker (LMW 97
to 14.4 kDa). Lane 2. Fraction of purified anti-intimin scFv, with 26.5
kDa indicated by the arrow.
C
A
C-terminus 
(Lys667)
C-terminus 
(Lys667)
B
Figure 5 scFv-intimin and intimin molecular structure.
Constructed models based on the predicted structures of conserved
intimin and recombinant anti-intimin scFv. A. Conserved intimin
(int388-667) [GenBank:CAS11487]. B. Anti-intimin scFv (heavy chain in
green, light chain in blue and linker in yellow). C. Interaction
between conserved intimin and anti-intimin scFv as predicted by
the programs ZDOCK and Rosetta Dock.
75
37,5
18,75
9,38
4,69
0.00
0.25
0.50
0.75
1.00
A
4
9
2
 
n
m
Concentration of rabbit anti-intimin IgG
enriched fraction (μg/ml) 
* 
Figure 6 Functional assay of anti-intimin scFv by indirect
sandwich ELISA. Microplates were coated with a serial dilution of
anti-intimin scFv, followed by incubation with 2 μg/mL of purified
intimin and a serial dilution of rabbit anti-intimin IgG enriched
fraction antibody. The graph shows the best fit titration curve of
275 ng of anti-intimin scFv reacting with 2 μg of purified intimin in
which the optimal absorbance was defined by 7.5 μg rabbit anti-
intimin IgG enriched fraction antibody (*).
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anti-intimin antibody able to detect the current known
intimin subtypes and further uncharacterized ones
[18-20].
In a previous work, even with an affinity constant of
1.3 × 10
-8 M and a good detection limit with purified
intimin, monoclonal anti-intimin IgG2b antibody
detected 78% of a wide range of EPEC and EHEC inti-
min-expressing strains [20]. These promising results
prompted the objective of this work, the production of a
functional scFv (corresponding to monoclonal anti-inti-
min antibody) intended for diagnosis purposes.
To outline our strategy, the pAE vector was used for
scFv expression which was constructed on the basis of
the pRSET vector containing the origin of replication of
high copy number, with the multiple cloning site con-
taining 6 histidine residues from the pET3-His vector
[32]. This vector was used successfully by others
[32,42-48], and despite the fact that in this study the
protein was expressed in an insoluble form, a good yield
was obtained.
In order to analyze the expression level of recombi-
nant scFv in E. coli, different host strains were used,
namely BL21(DE3)pLys and C43(DE3). These strains
prevent the escape of expression and contribute to an
over expression of the recombinant protein after induc-
tion. The analysis of expression in the C43(DE3) strain
showed the presence of a protein of predicted molecular
weight of 26.5 kDa, and another of smaller size (data
not shown). This could be due to action of a protease
that could be expressed in this strain. Another hypoth-
esis is that the presence of rare codons in the scFv
sequence could lead to truncated protein forms in this
strain. On the other hand, despite the presence of some
protein before induction, recombinant E. coli BL21(DE3)
pLys successfully expressed scFv with the expected
molecular weight. These results showed that E. coli
BL21(DE3)pLys expressed more protein and only the
predicted one. Thus, this strain was chosen for the
expression of scFv anti-intimin.
Expression in the reducing environment of the cyto-
plasm can be achieved at high concentrations but often
results in the formation of inclusion bodies (i.e., reduced
and unfolded proteins), where the product requires solu-
bilization with denaturing agents (e.g.,8Mu r e a )a n d
subsequent refolding, by dialysis, of the denaturing
agent in the presence of a redox pair (e.g., reduced and
oxidized glutathione). Refolding efficiency varies for dif-
ferent antibodies [49]. The anti-intimin scFv obtained in
this work was also expressed as insoluble bodies, and
thus, it was necessary to perform denaturing solubiliza-
tion with subsequent refolding steps.
The method chosen for recovering insoluble protein
was the solubilization in Tris-HCl buffer containing 8 M
urea, followed by purification and step-wise dialysis for
the refolding of the purified protein by decreasing urea
concentration. Anti-intimin scFv was expressed with 6
histidine residues at the N-terminal, for the purpose of
purification by metal affinity. In addition to purification,
the His-tag is an epitope for detection using specific
antibodies. To demonstrate the functionality of the scFv
by ELISA, purified intimin conserved domain (Int388-667)
is the best reagent for detection. However, the simple
fact that the purified intimin also contains His-tag
clearly impairs scFv detection, since the former could
create false positive results.
To overcome this technical limitation, the strategy
used was the sandwich indirect ELISA assay using the
rabbit IgG enriched fraction or monoclonal anti-intimin.
This protocol consisted of coating the plate with anti-
A  B 
Figure 7 Functional assay of scFv-intimin by immunofluorescence. A. EPEC E2348/69 strain permeabilized with 4% Triton X-100 followed by
incubation with 4.4 μg of anti-intimin scFv. The reaction was developed using anti-His antibody and anti-mouse IgG conjugated to FITC. B. E.
coli K12 JM109 (negative control) assayed as described for A.
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min and rabbit polyclonal anti-intimin IgG, without the
use of anti-His. Results showed that anti-intimin scFv is
a functional antibody, and as expected, the polyclonal
antibody does not compete with the scFv for the same
epitope. On the other hand, no reactivity was observed
when the monoclonal anti-intimin antibody was used,
suggesting that this antibody competes with the scFv for
t h es a m ei n t i m i ne p i t o p e( d a t an o ts h o w n ) .M o r e o v e r ,
anti-intimin scFv was tested by immunofluorescence.
This antibody recognized the EPEC E2348/69 strain but
not E. coli K-12 after outer membrane permeabilization,
showing its specificity for intimin.
The results of this study allow us to conclude that recom-
binant anti-intimin scFv was able to recognize the con-
served region of purified intimin (Int388-667) and intimin in
an EPEC isolate. Subsequent tests underway in our labora-
tory could demonstrate if the scFv reacts with the different
types of intimin expressed by EPEC and EHEC. These data
will be extremely important, since the recombinant scFv
described so far is derived from spleen cell-cDNA from
rabbits immunized with the intimin variable portion of
O157:H7 and recognize only gamma intimin [28]. It is
worth mentioning that our previous results already showed
that monoclonal anti-intimin antibody recognizes a broad
variety of EPEC and EHEC strains [20], and as the anti-inti-
min scFv described herein is derived from it, this rAb is a
promising tool for EPEC/EHEC diagnosis.
Conclusions
In conclusion, we successfully obtained a recombinant
anti-intimin scFv with high specificity for intimin,
detecting the conserved region of intimin (Int388-667)i n
the purified form and intimin on an EPEC isolate. Thus,
this rAb is a very promising tool for EPEC/EHEC diag-
nosis and research purposes. Also, the deduced amino
acid sequences of CDRs may also help us to create
other scFv fragments with even higher affinity and spe-
cificity for intimin by site-directed mutagenesis.
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